VI Partners — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Somagenetixsomagenetix.cominOct 2024
Somagenetix develops gene therapies for phagocyte disorders using a platform based on lentivirus-transduced stem cells designed for one-time treatments with cellular specificity.
BiotechDeep TechHealthtech
Co-investorsVerve Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.